Gliatilin in the Treatment of Cognitive Impairments Not Reaching the Level of Dementia: Meta-Analysis and Systematic Review
The main challenge during the analysis was methodological, population, and statistical heterogeneity, which required not only the use of a random effects model but also active search and exclusion of some sources. However, despite several limitations, the internal consistency and absence of contradictions in the analysis results demonstrated the robustness of the evidence obtained. The inclusion of a highly effective drug in the specialized medical care system will ensure the availability of cognitive impairment treatment programs and improve patients' quality of life.
Authors
- Natalia Shusharina (ORCID: https://orcid.org/0000-0002-8848-6134)
- Д.В. Токарева (ORCID: https://orcid.org/0000-0001-9746-5370)
- Mariia V. Prokhorova (ORCID: https://orcid.org/0000-0003-3412-0038)
- Т. В. Сергеева (ORCID: https://orcid.org/0000-0003-2949-6268)
- I. A. Voznjouk (ORCID: https://orcid.org/0000-0002-0340-4110)
- Anna Kutkova (ORCID: https://orcid.org/0009-0001-5825-9686)
- I.S. Nepomnyashchiy (ORCID: https://orcid.org/0009-0005-7141-3050)
Institutions
- Immanuel Kant Baltic Federal University (RU)
- First Pavlov State Medical University of St. Petersburg (RU)
- Saint Petersburg State Pediatric Medical University (RU)
Publication Details
- Journal
- S S Korsakov Journal of Neurology and Psychiatry
- Published
- 2025-12-09
- DOI
- https://doi.org/10.17116/jnevro202512511186
- Primary Topic
- Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00